Compare VHI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHI | ADCT |
|---|---|---|
| Founded | 1932 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 405.3M | 431.2M |
| IPO Year | 1994 | 2019 |
| Metric | VHI | ADCT |
|---|---|---|
| Price | $14.49 | $1.05 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $12.00 | $7.75 |
| AVG Volume (30 Days) | 13.4K | ★ 2.7M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.19% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $2,077,000,000.00 | $81,357,000.00 |
| Revenue This Year | $33.32 | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $207.00 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $11.44 | $0.78 |
| 52 Week High | $20.00 | $4.98 |
| Indicator | VHI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.96 | 15.76 |
| Support Level | $13.64 | N/A |
| Resistance Level | $15.45 | $4.77 |
| Average True Range (ATR) | 0.57 | 0.18 |
| MACD | 0.11 | -0.19 |
| Stochastic Oscillator | 91.92 | 9.41 |
Valhi Inc is a holding company that provides chemicals, security products, waste management systems, and real estate development and management services through its subsidiaries. It operates its business in three segments, which are Chemicals, Component Products, and Real Estate Management and Development. The company derives maximum revenue from the Chemicals segment, which produces and markets value-added titanium dioxide pigments (TiO2). TiO2 is used to impart whiteness, brightness, opacity, and durability to various products, including paints, plastics, paper, fibers, and ceramics. Geographically, the company generates maximum revenue from the United States and also has a presence in Germany, Canada, Norway, and Belgium.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).